Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.
ACS Med Chem Lett
; 3(1): 63-8, 2012 Jan 12.
Article
en En
| MEDLINE
| ID: mdl-24900372
ABSTRACT
Structure-guided optimization of a series of C-5 alkyl substituents led to the discovery of a potent nicotinic acid receptor agonist SCH 900271 (33) with an EC50 of 2 nM in the hu-GPR109a assay. Compound 33 demonstrated good oral bioavailability in all species. Compound 33 exhibited dose-dependent inhibition of plasma free fatty acid (FFA) with 50% FFA reduction at 1.0 mg/kg in fasted male beagle dogs. Compound 33 had no overt signs of flushing at doses up to 10 mg/kg with an improved therapeutic window to flushing as compared to nicotinic acid. Compound 33 was evaluated in human clinical trials.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
ACS Med Chem Lett
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos